These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 20570692)

  • 21. Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression.
    Han M; Deng C; Burne TH; Newell KA; Huang XF
    Psychoneuroendocrinology; 2008 Jun; 33(5):569-80. PubMed ID: 18358632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats.
    Victoriano M; Hermier D; Even PC; Fromentin G; Huneau JF; Tomé D; de Beaurepaire R
    Psychopharmacology (Berl); 2009 Sep; 206(1):167-76. PubMed ID: 19572122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance.
    Lykkegaard K; Larsen PJ; Vrang N; Bock C; Bock T; Knudsen LB
    Schizophr Res; 2008 Aug; 103(1-3):94-103. PubMed ID: 18579346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of olanzapine-induced weight gain by the retinoid analog AM-80.
    Richards M; Chiba S; Ninomiya M; Wakabayasi C; Kunugi H
    Pharmacopsychiatry; 2013 Nov; 46(7):267-73. PubMed ID: 24105080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine treatment and metabolic dysfunction: a dose response study in female Sprague Dawley rats.
    Weston-Green K; Huang XF; Deng C
    Behav Brain Res; 2011 Mar; 217(2):337-46. PubMed ID: 21056063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Olanzapine reduces physical activity in rats exposed to activity-based anorexia: possible implications for treatment of anorexia nervosa?
    Hillebrand JJ; van Elburg AA; Kas MJ; van Engeland H; Adan RA
    Biol Psychiatry; 2005 Oct; 58(8):651-7. PubMed ID: 16018979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.
    van der Zwaal EM; Luijendijk MC; Adan RA; la Fleur SE
    Eur J Pharmacol; 2008 May; 585(1):130-6. PubMed ID: 18378227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.
    Cooper GD; Harrold JA; Halford JC; Goudie AJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):428-36. PubMed ID: 17933447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents.
    Albaugh VL; Henry CR; Bello NT; Hajnal A; Lynch SL; Halle B; Lynch CJ
    Obesity (Silver Spring); 2006 Jan; 14(1):36-51. PubMed ID: 16493121
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration.
    Minet-Ringuet J; Even PC; Goubern M; Tomé D; de Beaurepaire R
    Appetite; 2006 May; 46(3):254-62. PubMed ID: 16551485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatment.
    Lian J; Huang XF; Pai N; Deng C
    PLoS One; 2014; 9(8):e104160. PubMed ID: 25084453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of olanzapine-induced weight gain with an increase in body fat.
    Eder U; Mangweth B; Ebenbichler C; Weiss E; Hofer A; Hummer M; Kemmler G; Lechleitner M; Fleischhacker WW
    Am J Psychiatry; 2001 Oct; 158(10):1719-22. PubMed ID: 11579009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain.
    Belanoff JK; Blasey CM; Clark RD; Roe RL
    Diabetes Obes Metab; 2010 Jun; 12(6):545-7. PubMed ID: 20518810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different effects of bifeprunox, aripiprazole, and haloperidol on body weight gain, food and water intake, and locomotor activity in rats.
    De Santis M; Pan B; Lian J; Huang XF; Deng C
    Pharmacol Biochem Behav; 2014 Sep; 124():167-73. PubMed ID: 24933333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects.
    Girault EM; Guigas B; Alkemade A; Foppen E; Ackermans MT; la Fleur SE; Fliers E; Kalsbeek A
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Feb; 387(2):185-95. PubMed ID: 24190543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice.
    Yoon S; Noh JS; Choi SY; Baik JH
    Biochem Biophys Res Commun; 2010 Mar; 393(2):235-41. PubMed ID: 20117094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.
    Beebe KL; Block T; Debattista C; Blasey C; Belanoff JK
    Behav Brain Res; 2006 Aug; 171(2):225-9. PubMed ID: 16782211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic administration of olanzapine affects Behavioral Satiety Sequence and feeding behavior in female mice.
    Coccurello R; D'Amato FR; Moles A
    Eat Weight Disord; 2008 Sep; 13(3):e55-60. PubMed ID: 19011365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevation of systolic blood pressure in an animal model of olanzapine induced weight gain.
    Patil BM; Kulkarni NM; Unger BS
    Eur J Pharmacol; 2006 Dec; 551(1-3):112-5. PubMed ID: 17046744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic and behavioral effects of chronic olanzapine treatment and cafeteria diet in rats.
    Muller AP; Tort AH; Gnoatto J; Moreira JD; Vinadé ER; Perry ML; Souza DO; Lara DR; Portela LV
    Behav Pharmacol; 2010 Oct; 21(7):668-75. PubMed ID: 20729714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.